You are here

  • Home
  • Archive
  • Volume 79, Issue 5
  • Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study

Citation Tools

Article menu

This article has corrections. Please see:

Download PDFPDF

XML
Spondyloarthritis
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
van der Heijde D, Gensler LS, Deodhar A, et al
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
Annals of the Rheumatic Diseases 2020;79:595-604.